CD34 and ischemic disease: The practicality of procedures, such as mesenchymal stem cell therapy, BM MNC or PBMNC therapy, and CD34+ cell therapy for treating ischemic diseases remain limited.51,52 These treatments require multiple days of injection and apheresis sessions or liposuction and are associated with relatively higher levels of complications, risk, technical challenges, and patient burden.